In this study, we show that the ETS transcription factor ER81 directly binds to and activates the promoter of the matrix metalloproteinase gene, MMP-1. Further, the oncoprotein HER2/Neu synergizes with ER81 to stimulate MMP-1 transcription. The activation of ER81 by HER2/Neu is mediated by MAP kinases, which phosphorylate ER81 in its N-terminal activation domain. Four respective phosphorylation sites have been identi®ed. Blocking phosphorylation at these sites decreases ER81 transcriptional activity, which can be further diminished by abolishment of phosphorylation at two non-MAP kinase sites. Altogether, our results reveal mechanisms of how phosphorylation of ER81 regulates the expression of target genes such as MMP-1, which may be important for many physiological processes from embryogenesis to adulthood as well as for tumor metastasis. Oncogene (2001) 20, 6215 ± 6224.
Introduction
Matrix metalloproteinases (MMPs) are zinc-dependent proteases that are required for a plethora of physiological processes such as tissue remodeling and repair, embryonic development, skeletal morphogenesis, and angiogenesis. In addition to their normal cellular functions, MMPs also contribute to the development of diseases, including pulmonary emphysema, osteoarthritis, and cancer (Nelson et al., 2000) .
One member of the MMP family responsible for initiating the degradation of collagen, the body's most abundant protein, is interstitial collagenase (MMP-1). MMP-1 expression can occur in a broad variety of cell types such as dermal ®broblasts, keratinocytes, smooth muscle cells, endothelial cells and macrophages. In addition, atypical levels of MMP-1 expression have been linked to various types of tumors (Brummer et al., 1999; Garbett et al., 2000; Sunami et al., 2000) and transgenic mice that express human MMP-1 display increased rates of skin tumor incidence (D'Armiento et al., 1995) . These observations suggest that MMP-1 (over)expression contributes to the development of cancer, presumably through the ability of MMP-1 to break down collagen of the extracellular matrix thereby facilitating tumor invasion and spreading. Indeed, chemical inhibitors or antisense oligonucleotides directed against the MMP-1 protein or mRNA can reduce the invasiveness of cancer cells (Benbow et al., 1999; Durko et al., 1997; Nelson et al., 2000) .
MMP-1 expression is activated by many stimuli, including growth factors, in¯ammatory interleukins, heat or UV-light (Fini et al., 1998) . These signals can lead to the stimulation of mitogen-activated protein (MAP) kinases, which appear to be required for transcriptional activation of the MMP-1 gene (Johansson et al., 2000; Reunanen et al., 1998) . In addition, MMP-1 promoter activity may be regulated through DNA sites capable of interacting with ETS proteins (Buttice et al., 1996; Higashino et al., 1995; Westermarck et al., 1997) , a family of transcription factors related to each other by a conserved DNA binding domain (Graves and Petersen, 1998) .
The ETS protein Elk-1 was among the ®rst transcription factors shown to be a direct target of MAP kinases. Elk-1 is recruited by the serum response factor to the promoter of the c-fos protooncogene, where it is constitutively bound before, during and after c-fos transcriptional upregulation in response to growth factors, phorbol ester or cell stressors (Treisman, 1995) . These signals activate distinct classes of MAP kinases: the ERK-MAP kinases that are primarily activated by growth factors, and the stressactivated MAP kinases, JNK and p38 (Garrington and Johnson, 1999) . ERK-, JNK-and p38-MAP kinases are capable of phosphorylating Elk-1 at multiple sites in its C-terminal activation domain, thereby triggering c-fos transcription (Cahill et al., 1996; Wasylyk et al., 1998) . Furthermore, the prototypical ETS proteins Ets-1 and Ets-2 are activated by Ras-dependent signaling pathways through the phosphorylation of one respective critical threonine residue by ERK-MAP kinases (McCarthy et al., 1997; Yang et al., 1996) . However, MAP kinase phosphorylation does not always functionally activate ETS proteins. For instance, eye development in Drosophila is dependent on the action of two antagonizing ETS factors, the repressor Yan and the activator Pointed-P2, which can compete for binding to the same DNA sites. Whereas Pointed-P2 is activated by MAP kinase phosphorylation, Yan function is negatively regulated by MAP kinases (Brunner et al., 1994; O'Neill et al., 1994) .
Another member of the ETS protein family, whose transcriptional activity is stimulated by the ERKsubclass of MAP kinases, is ER81 (Brown and McKnight, 1992; Janknecht, 1996) . However, it is hitherto unknown whether ER81 is regulated in its activity by direct MAP kinase phosphorylation. Northern blot analysis revealed that ER81 is expressed in a tissue-speci®c manner. For instance, ER81 mRNA levels are high in brain and testis, but hardly detectable in liver or skeletal muscle (Brown and McKnight, 1992; Monte et al., 1995) . Furthermore, ER81 expression is spatially and temporally controlled throughout mouse organogenesis (Chotteau-Lelievre et al., 1997), suggesting an important role for ER81 in development. Consistent with this notion, a mouse knock-out model for ER81 revealed severe motor discoordination due to defects in the connection between sensory and motor neurons in the developing spinal cord (Arber et al., 2000) .
Here, we demonstrate that MMP-1 is a potential target gene of ER81. Furthermore, we have uncovered mechanisms of ER81 activation through phosphorylation by MAP kinases, explaining how gene expression could be regulated by ER81 and a MAP kinase activator such as the HER2/Neu oncoprotein.
Results

ER81 regulates the MMP-1 promoter
Hitherto, the transcriptional activity of the ER81 protein has been assessed with the help of two reporter constructs driven by multimerized ETS binding sites derived from either the Drosophila E74 gene or from the polyomavirus enhancer (Janknecht, 1996; Monte et al., 1995) . In order to identify a physiological target gene for the ER81 protein, we searched the literature for gene promoters regulated by ETS binding sites. One such promoter is the MMP-1 one (Buttice et al., 1996; Higashino et al., 1995; Westermarck et al., 1997) . Hence, we utilized a luciferase reporter construct driven by the human MMP-1 promoter (nucleotides 7525 to +15) in transient transfection experiments to analyse whether ER81 can aect MMP-1 transcription. Indeed, as shown in Figure 1 , the MMP-1 reporter plasmid was activated *threefold upon ER81 expression. In contrast, the parental luciferase expression vector pGL2-Basic was not aected by ER81.
In order to identify the critical ER81 responsive element(s) within the MMP-1 promoter, we subcloned progressively shorter fragments of the MMP-1 promoter in front of the luciferase reporter gene. This approach enabled us to localize a region between nucleotides 741 and 791 of the MMP-1 promoter that is pivotal for transcriptional upregulation upon ER81 expression as well as for the basal level of MMP-1 gene activity (Figure 1) . Examination of the nucleotide sequence within this region revealed two putative ER81 binding sites conforming to the canonical GGA A / T core-sequence crucial for DNA binding by the ETS domain of ER81 (Brown and McKnight, 1992; Graves and Petersen, 1998) . The contribution of each of these two elements to the ER81-mediated regulation of MMP-1 was assessed through mutating the two guanines of the coresequence. Using this strategy, we discovered that mutation of residues 787/788 (Figure 2a ), but not residues 747/748 (data not shown), from GG to AA dramatically dampened ER81-mediated transcription. These data are consistent with previous reports demonstrating the importance of residues 787/788 for MMP-1 promoter activity (Buttice et al., 1996; Higashino et al., 1995; Westermarck et al., 1997) .
In addition, we analysed whether ER81 could interact with the MMP-1 promoter. To this end, binding of a puri®ed C-terminal ER81 fragment to MMP-1 promoter nucleotides 797 to 762 was tested in electrophoretic mobility shift assays (Figure 2b,c) . ER81 was indeed capable of binding to this 32 P-labeled MMP-1 promoter fragment. This binding was speci®c, since it could be competed by an established ER81 binding site, E74 (Janknecht, 1996) , but not by a mutated E74 oligonucleotide unable to associate with ER81 ( Figure 2b) . Similarly, the non-radiolabeled MMP-1 oligonucleotide suppressed the formation of the ER81/ 32 P-DNA complex, whereas the MMP-1 oligonucleotide mutated at positions 787 and 788 did not (Figure 2b ). Altogether, ER81 can bind to the MMP-1 promoter at the ETS binding site encompassing the GGAT core-sequence from 788 to 785 and thereby stimulate basal MMP-1 promoter activity.
HER2/Neu stimulates ER81 transcriptional activity
ER81-dependent transcription is enhanced by ERK-MAP kinases (Janknecht, 1996) and MAP kinases themselves can be activated by the transmembrane receptor tyrosine kinase HER2/Neu (Hung and Lau, 1999) . Thus, we speculated that HER2/Neu may stimulate ER81 which in turn would activate MMP-1. In order to test this hypothesis, we coexpressed ER81 and an oncogenic version of HER2/Neu, HER2/Neu-V664E (Ben-Levy et al., 1994) , and assayed the activity of the MMP-1 luciferase reporter construct ( Figure 3a ). As shown above, ER81 on its own slightly stimulates the MMP-1 promoter (black bar), and mutation of the ER81 binding site in the MMP-1 promoter abolished this activation (grey bar). Similarly, oncogenic HER2/ Neu on its own slightly activated the MMP-1 promoter, and this activation was nearly abrogated with the mutated MMP-1 promoter, suggesting that endogenous ER81 or ER81-like proteins mediate this HER2/Neu response. Importantly, coexpression of HER2/Neu and ER81 resulted in a strong synergistic activation of the MMP-1 promoter, which was reduced by 86% upon mutation of the critical ER81 binding site in the MMP-1 promoter. A control Western blot ( Figure 3a , bottom panel) revealed that HER2/Neu overexpression did not signi®cantly aect the levels of coexpressed ER81. In conclusion, binding of ER81 to its cognate site in the MMP-1 promoter facilitates strong MMP-1 induction by HER2/Neu.
The human MMP-1 promoter encompasses from position 773 to 767 a binding site for the transcription factor AP1, TGAGTCA (see Figure 2c) , that has been shown to be involved in MMP-1 regulation (Fini et al., 1998) . Mutation of this site to TGATGGA in the MMP-1 (7525/+15) luciferase reporter construct resulted in luciferase activity comparable to the parental luciferase reporter construct, pGL2-Basic (Figure 3b ), which is *20-fold lower than that of the wild-type MMP-1 (7525/+15) construct (see Figure 1) . Furthermore, expression of ER81 did not stimulate the MMP-1 promoter with the mutated AP1 site (Figure 3b ), suggesting that the eect of ER81 on basal MMP-1 promoter activity is dependent on AP1. However, coexpression of ER81 and HER2/Neu was still able to *®vefold stimulate the AP1-site mutated MMP-1 promoter, yet even this level of activity is still *fourfold less than the basal activity of the wild-type promoter. Thus, ecient HER2/Neu-mediated activation of the MMP-1 promoter is dependent on both the AP1 and the ER81 binding site.
Next, we tested if ER81 and HER2/Neu are also able to increase expression of the endogenous MMP-1 gene. Thus, we expressed ER81 by itself or in conjunction with oncogenic HER2/Neu in human 293T cells. These cells do not display any detectable MMP-1 expression with our reverse transcriptase polymerase chain reaction (RT ± PCR) assay system ( Figure 3c ). Also, ER81 expression alone did not cause detectable MMP-1 expression, whereas HER2/Neu expression did. This indicated that HER2/Neu, potentially via endogenous ER81, can upregulate the MMP-1 promoter. Indeed, we were able to detect expression of endogenous ER81 in 293T cells (Figure 3d ). Furthermore, co-transfection of ER81 with HER2/Neu resulted in a strong enhancement of the MMP-1 signal compared to HER2/Neu alone ( Figure 3c ). Again, HER2/Neu overexpression did not aect the levels of coexpressed ER81 (see Figure 3c , bottom panel).
Collectively, our data demonstrate that HER2/Neu and ER81 can collaborate to greatly enhance transcription of the MMP-1 gene.
HER2/Neu overexpression is often observed in breast cancer patients and correlates with a poor prognosis (Hung and Lau, 1999) . We wondered whether ER81 is expressed in breast tumors and could thus potentially serve the function of a downstream eector of oncogenic HER2/Neu in breast cancer. RT ± PCR analysis of 11 human breast tumor samples revealed ER81 expression in all tumors ( Figure 3e ). In contrast, only four of these tumor samples displayed MMP-1 expression ( Figure 3e , lanes 2, 3, 4 and 9), and their degree of MMP-1 expression was highly variable. Future studies should elucidate whether the degree of MMP-1 expression correlates with HER2/Neu overexpression, or other changes (e.g., the presence of oncogenic Ras) leading to enhanced MAP kinase signaling and thus also to the activation of ER81. 
HER2/Neu induces phosphorylation and activation of ER81 via MAP kinases
To determine whether HER2/Neu-triggered activation of ER81 correlates with increased phosphorylation of ER81, we expressed ER81 in 293T cells in the absence or presence of oncogenic HER2/Neu. The cells were treated with 32 P-orthophosphate and the resulting radiolabeled ER81 was immunopuri®ed. Equivalent small aliquots (10%) were then processed for determination of ER81 protein levels, which were comparable as judged by Western blotting ( Figure  4a ). The majority (90%) of the immunopuri®ed ER81 was subjected to preparative SDS-polyacrylamide gel electrophoresis. Then, the radiolabeled ER81 proteins were eluted from the gel, digested with trypsin and the resulting phosphopeptides separated in two dimensions on thinlayer chromatography plates. While little phosphorylation of ER81 was observable in the absence of HER2/Neu, coexpression of HER2/Neu with ER81 resulted in increased phosphorylation distributed over several phosphopeptides (Figure 4b , left two panels). These data indicate that HER2/Neu can elicit the phosphorylation of ER81 at multiple sites, presumably via MAP kinases.
Three dierent subclasses of MAP kinases exist in the mammalian cell, the ERK-, JNK-and p38-MAP kinases (Garrington and Johnson, 1999) . In order to elucidate whether and which MAP kinases are (1 mg) and HER2/Neu-V664E (1 mg), as indicated. Cytosolic RNA isolated from these cells was utilized for RT ± PCR analysis of MMP-1 and, as a control, of GAPDH expression. As in (a), comparable expression of ER81 was observed in the presence and absence of HER2/Neu (bottom panel). (d) Antibodies raised against ER81 amino acids 129 ± 210 were utilized in a Western blot analysis of a 293T cell lysate. The respective preimmune serum was utilized as a control. The calculated molecular weight of human ER81 is 55 kDa. (e) RT ± PCR analysis of human breast tumor samples. Equal amounts of RNA were employed for the detection of ER81 and MMP-1 expression involved in the stimulation of ER81-and HER2/Neumediated transcription, we utilized dierent inhibitors of the MAP kinase signaling pathways: U0126, which blocks activation of ERK-MAP kinases (Favata et al., 1998) , and SB202190, which inhibits p38-MAP kinases (Lee et al., 1994) . Administration of U0126 and/or SB202190 did not signi®cantly aect the activation of the basal MMP-1 promoter activity by ER81 ( Figure  5a ). However, HER2/Neu-dependent activation of ER81 was signi®cantly mitigated upon addition of either U0126 or SB202190, and addition of both inhibitors further reduced the ability of HER2/Neu to stimulate ER81. Altogether, these data indicate that HER2/Neu-dependent activation of ER81 is transduced predominantly by ERK-and p38-MAP kinases, whereas JNK-MAP kinases might not play a major role.
To further demonstrate that the transcriptional activity of ER81 on the MMP-1 promoter can be modulated by ERK-and p38-MAP kinases, we coexpressed ER81 with BXB, which is a constitutively active Raf-1 molecule speci®cally activating the ERK-MAP kinase pathway (Bruder et al., 1992) , or with MEK6(DD), a speci®c activator of p38-MAP kinases (Stein et al., 1997) . BXB greatly increased ER81-dependent activation of the MMP-1 promoter, which also held true for MEK6(DD) (Figure 5b ). These data corroborate that ERK-and p38-MAP kinases are able to activate ER81-mediated MMP-1 transcription. We also activated JNK-MAP kinases with the speci®c upstream activator MKK7a (Holland et al., 1997) under various conditions. However, we were never able to obtain more than a slight (less than 2.5-fold) activation of ER81-dependent transcription (data not shown). Thus, JNK-MAP kinases may target ER81 in vivo, but less eciently than ERK-and p38-MAP kinases.
Identification of MAP kinase phosphorylation sites in ER81
Analysis of the ER81 protein sequence revealed six potential phosphorylation sites conforming to the MAP kinase consensus sequence, (P)X S / T P (Clark- Lewis et al., 1991; Treisman, 1996) , that are all located within the N-terminal activation domain of ER81 (Janknecht, 1996) . These residues are serine 94, threonine 139, threonine 143, serine 146, serine 152 and threonine 158 (Figure 6a ). All these potential phosphorylation sites are encompassed by the GST (glutathione S-transferase)-ER81(63 ± 182) fusion protein, in which respective alanine point mutations were introduced. The wild-type and mutant GST-ER81(63 ± 182) fusion proteins were then utilized in in vitro kinase assays with ERK1-MAP kinase as described (Janknecht, 1996) and subjected to phosphopeptide analyses (Figure 6b ). The wild-type fusion protein revealed two prominent phosphopeptides (d and e). Mutation of serine 94 to alanine eliminated these phosphopeptides as well as phosphopeptide f. Since trypsin cleaves ineciently an N-terminal lysine (van der Geer and Hunter, 1994), phosphopeptides d and e represent amino acids 90 ± 110 and 91 ± 110, respectively, which dier by one positively charged lysine residue (see Figure 6a ). Phosphopeptide f is most likely due to incomplete reaction with performic acid, which is utilized to oxidize cysteine and methionine residues before the trypsin digestion (van der Geer and Hunter, 1994). In contrast, mutation of serine 152 and threonine 158 to alanine had no eect on the phosphopeptide pattern (Figure 6b ), indicating that none of these sites is utilized by ERK1. On the other hand, the A139/143/146 mutant lost phosphopeptides g and h. Since threonine 139, threonine 143 and serine 146 are all contained within one tryptic fragment, this suggests that two out of these three amino acids are phosphorylated, with phosphopeptide h being the monophosphorylated one and phosphopeptide g representing two phosphorylation events. Indeed, phosphoamino acid analysis of the A94 mutant revealed both phosphoserine and phosphothreonine (data not shown), indicating that serine 146 as well as threonine 139 or threonine 143 are phosphorylated.
Tryptic phosphopeptide maps of GST-ER81(63 ± 182) phosphorylated by JNK1 or p38-2 revealed the same phosphopeptides d ± h (Figure 6c ). JNK1 did not eciently phosphorylate serine 94, hence the phosphopeptides d ± f are barely visible. In addition to phosphopeptides d ± h, another phosphopeptide i was observable in case of p38-2 phosphorylation ( Figure  6c ). The position of peptide i relative to the peptides g and h strongly suggests that this phosphopeptide represents phosphorylation at three sites (van der Geer and Hunter, 1994), namely threonine 139, threonine 143 and serine 146. Consistently, the A139/143/146 mutant did not reveal phosphopeptides g ± i upon p38-2 phosphorylation (data not shown). We conclude that MAP kinases can phosphorylate ER81 at residues 94, 139, 143 and 146 in vitro.
An inspection of the phosphopeptide map of in vivo 32 P-labeled ER81 (see Figure 4b , bottom left panel) indicated that phosphopeptides d ± i are present in fulllength ER81 (phosphopeptides g and h are clearly visible upon longer exposure of the autoradiogram, yet the preponderance of phosphopeptide i suggests a predominantly simultaneous phosphorylation at residues 139, 143 and 146 in vivo). Indeed, mixing phosphopeptides derived from ERK1-phosphorylated GST-ER81(63 ± 182) and from in vivo 32 P-labeled ER81 demonstrated that those phosphopeptides comigrated and are thus equivalent to each other (see Figure 4b) . Furthermore, phosphopeptides d ± i vanished in in vivo 32 P-labeled ER81 upon introduction of alanine residues at positions 94, 139, 143 and 146 (data not shown). These data indicate that serine 94, threonine 139, threonine 143 and serine 146 are phosphorylated by MAP kinases in vivo. In addition, we have previously reported the identi®cation of the phosphorylation sites corresponding to phosphopeptides a ± c (see Figure 4b) . The respective phosphorylation sites are serine 191 and serine 216 (Papoutsopoulou and Janknecht, 2000) , which are not phosphorylated by MAP kinases.
MAP kinase phosphorylation regulates ER81 activity
Having identi®ed all major in vivo phosphorylation sites within ER81, we introduced alanine residues at the respective serine and threonine residues in the full- length ER81 molecule in order to measure their impact on ER81 transcriptional activity. First, we tested whether protein stability would be altered by these mutations. As shown in Figure 7a , protein levels varied at most twofold between the wild-type and the mutant ER81 molecules. In order to exclude that twofold variations of ER81 protein could aect our transactivation data, we employed an amount of ER81 expression vector (1 mg) that gave comparable transactivation of the MMP-1 luciferase reporter plasmid as twofold higher or lower amounts. Under these conditions, the ER81 mutants were then tested for their ability to activate the MMP-1 promoter in response to oncogenic HER2/Neu (Figure 7b ). Mutation of serine 94 to alanine did not result in a signi®cant change of ER81-mediated transcription. On the other hand, the triple alanine mutant A139/ 143/146 retained only roughly half of the transcriptional activity upon HER2/Neu expression, as did the A191/216 mutant. Joint mutation of the phosphorylation sites at position 139, 143, 146, 191 and 216 to alanine reduced transcriptional activity of ER81 upon HER2/Neu expression by 4.6-fold. Additional mutation of serine 94 had no eect.
The MMP-1 promoter is regulated by various transcription factors, including AP1, that may also be targeted by HER2/Neu (Fini et al., 1998) and potentially collaborate with ER81. Thus, in order to measure more directly the transcriptional activity of ER81 alone, we utilized an arti®cial reporter construct solely driven by three ER81 binding sites (E74) (Janknecht, 1996) . Similar as with the MMP-1 promoter, ecient ER81-mediated activation of the E74-driven luciferase reporter was dependent on phosphorylation of ER81 at residues 139, 143, 146, 191 and 216 (Figure 7c ). Therefore, we conclude that phosphorylation of threonine 139, threonine 143 and serine 146 by ERK-or p38-MAP kinases is important for transcriptional activity of ER81, and that additional phosphorylation at serine 191 and serine 216 is required for maximal ER81 activation.
Discussion
Our studies have revealed a number of novel ®ndings: (i) ER81 is a downstream eector of HER2/Neu; (ii) HER2/Neu can activate ER81 via the ERK-and p38-MAP kinase pathways, and less eciently via JNK-MAP kinases; (iii) Direct MAP kinase phosphorylation of ER81 occurs at four sites in the N-terminal activation domain; (iv) MAP kinase phosphorylation of ER81 as well as its phosphorylation by a non-MAP kinase at serine 191 and serine 216 are both required for maximal transcriptional activity; (v) MMP-1 has been identi®ed as a potential target gene of both ER81 and HER2/Neu. Collectively, these ®ndings have elucidated mechanisms of ER81 activation and a way of how MMP-1 can be upregulated in normal and tumor cells by many stimuli or oncogenes triggering MAP kinase signaling pathways.
Our studies revealed that ER81 is phosphorylated at multiple sites in vivo. Most of these are direct MAP kinase phosphorylation sites, namely serine 94, threonine 139, threonine 143 and serine 146. Mutation of serine 94 to alanine had no eect on ER81 transcriptional activity, whereas mutation of the cluster of phosphorylation sites between position 139 ± 146 or at residues 191 and 216 decreased ER81 transcriptional activity upon HER2/Neu-mediated stimulation. Importantly, phosphorylation within the region 139 ± 146 and at serine 191 and 216 appear to collaboratively impact on ER81 activity. Serines 191 and 216 are not directly phosphorylated by MAP kinases, but their phosphorylation is induced upon HER2/Neu overexpression. Therefore, one likely possibility is that MAP kinases activate a downstream kinase, which then phosphorylates ER81 on serines 191 and 216. Indeed, we have identi®ed a MAP kinase-activated protein kinase that phosphorylates ER81 at these two serine residues (manuscript in preparation). This would suggest that ER81 is dually regulated through direct MAP kinase phosphorylation and phosphorylation by a MAP kinase-activated protein kinase(s).
Mutating all phosphorylation sites in ER81 did not completely abolish the ability of ER81 to enhance MMP-1 transcription upon HER2/Neu expression. This small residual MMP-1 induction by the A139/ 143/146/191/216 mutant of ER81 may be due to the fact that phosphorylation is not the only posttranslational modi®cation regulating ER81 activity. For instance, the transcription factors p53 and E2F1 display an enhanced ability to activate gene transcription upon acetylation (Gu and Roeder, 1997; MartinezBalbas et al., 2000) . Similarly, ER81 may be activated through acetylation, and the respective acetyl transferase(s) might be stimulated in their enzymatic function by MAP kinases. Alternatively, MAP kinases may not solely target ER81, but also factors which are tethered by ER81 to a gene promoter. One such factor is the coactivator and acetyltransferase CBP, which physically interacts with ER81 and stimulates ER81-dependent transcription (Papoutsopoulou and Janknecht, 2000) . Indeed, CBP can be phosphorylated by MAP kinases and this phosphorylation increases its transactivation potential (Janknecht and Nordheim, 1996; Liu et al., 1998) .
Mutation of the ER81 binding site in the MMP-1 promoter resulted in non-responsiveness towards HER2/Neu overexpression without aecting basal promoter activity (Figure 3a) , suggesting that ER81 is a pivotal target for HER2/Neu-triggered signaling leading to the stimulation of the MMP-1 gene. However, mutation of the AP1 binding site dramatically reduced MMP-1 promoter activity, yet HER2/ Neu in conjunction with ER81 was still slightly capable of activating MMP-1 promoter activity (Figure 3b ). These data suggest that AP1 binding is essential for both basal and HER2/Neu-triggered MMP-1 gene activity, whereas ER81 is only required for transcriptional upregulation mediated by HER2/Neu. This notion is consistent with previous reports demonstrating that the ER81 binding site in the MMP-1 promoter is an auxiliary element promoting induction by ®broblast growth factor, phorbol myristate acetate or insulin, which all activate MAP kinase signaling pathways (Chapman et al., 1999; Newberry et al., 1997; White et al., 1997) .
We report here for the ®rst time that ER81 is a downstream eector of HER2/Neu. Overexpression of this receptor tyrosine kinase is especially observed in *30% of all breast cancer patients, resulting in insensitivity to tamoxifen treatment and a poor prognosis (Hung and Lau, 1999). Since ER81 is expressed in various breast tumor cell lines (Baert et al., 1997) and in human breast tumor specimens (Figure 3e ), MMP-1 might be upregulated in many breast tumors as a result of the HER2/Neu ? MAP kinase ? ER81 signaling cascade. Indeed, whereas MMP-1 is typically not expressed in normal breast tissue, its expression has been observed in some breast carcinomas and appears to be inversely correlated to the expression of progesterone receptors (Brummer et al., 1999; Nakopoulou et al., 1999) . Similarly, HER2/Neu overexpression in breast tumors is correlated with reduced levels of progesterone and estrogen receptor mRNA (Hung and Lau, 1999) , supporting the notion that HER2/Neu induces MMP-1 expression in breast tumors.
ER81 is also expressed in the peripheral nervous system, where its function is essential for the development of proper nerve connections in the spinal cord (Arber et al., 2000) . One kind of peripheral nervous system tumor are schwannomas that can be induced transplacentally in embryos by the N-ethyl-Nnitrosourea carcinogen. Interestingly, N-ethyl-N-nitrosourea-induced schwannomas display oncogenic mutations in the HER2/Neu gene (Buzard et al., 1999; Kindler-Rohrborn et al., 2000; Nikitin et al., 1991) . Thus, one may speculate that ER81 is a downstream eector of oncogenic HER2/Neu in schwannomas and activates the MMP-1 and other target genes being involved in carcinogenesis. Indeed, whereas MMP-1 activity is very low in normal Schwann cells, elevated MMP-1 expression has been observed in Schwann tumor cells which may contribute to their metastatic potential (Muir, 1995) .
In conclusion, our results demonstrate how phosphorylated ER81 can regulate the MMP-1 gene and may thereby be involved in many physiological processes dependent on MMP-1 activity, such as wound repair, cartilage formation and implantation of the embryo into the uterus (Moll and Lane, 1990; Shingleton et al., 1996) . Furthermore, ER81 could promote expression of MMP-1 and other yet-to-beidenti®ed target genes in tumor cells characterized by enhanced MAP kinase activity. This may be important for the degree of tumor aggressiveness and lethality, especially in HER2/Neu-overexpressing tumors of the breast, ovary, stomach and colon (Hynes and Stern, 1994) .
Materials and methods
Luciferase assays
Rabbit kidney epithelial-like RK13 cells were transiently transfected by the calcium phosphate coprecipitation method. Thirty-six hours post transfection, luciferase activity was determined as described (Bredemeier-Ernst et al., 1997; Pearson et al., 1999) .
Electrophoretic mobility shift assays
Samples were incubated on ice for 1 h in 10 mM Tris-HCl pH 7.9, 5 mM MgCl 2 , 50 mM NaCl, 1 mM EDTA, 50 mg/ml BSA, 5% glycerol, 5 mM DTT, 0.1% IGEPAL CA-630, 0.1 mg/ml poly(dI-dC)*poly(dI-dC). ER81 (DNA binding Cterminal fragment 249 ± 477) used in these experiments was produced with the`IMPACT-CN System' (New England Biolabs). Furthermore, 1 ml of a polyclonal antibody directed against the C-terminus of ER81 (ETV-1 (C20); Santa Cruz) was utilized, which dramatically enhances DNA binding of ER81. Samples were electrophoresed in 4% polyacrylamide gels in 0.56TBE for 3 h at 48C. Gels were dried and exposed to ®lm.
Isolation of RNA
Cytoplasmic RNA was isolated from 293T cells grown in 60 mm culture dishes. Cells were washed with PBS, then lysed in 50 mM Tris-HCl pH 8, 100 mM NaCl, 5 mM MgCl 2 , 0.5% IGEPAL CA-630 prepared in DEPC treated water, and the lysate centrifuged. To the supernatant was added SDS to a ®nal concentration of 0.3% and proteinase K to 125 mg/ml. After incubation at 378C for 15 min, the RNA was extracted using phenol/chloroform/isoamyl alcohol, precipitated with 0.3 M sodium acetate and ethanol, and then dissolved in DEPC treated water. Total RNA was extracted from breast tissue frozen in OCT compound (Sakura) using TRIzol (Gibco ± BRL). Brie¯y, breast tissue specimens were sectioned (10 ± 20 mm) and placed in TRIzol. RNA was extracted by addition of chloroform and precipitated using isopropanol in the presence of 10 mg glycogen. RNA was dissolved in DEPC treated water. Human breast tissues were from anonymous donors, and their use for these experiments has been approved by the Mayo Institutional Review Board.
RT ± PCR
These analyses were carried out using the`Access RT ± PCR System' (Promega). 0.5 mg of RNA was utilized in a thermal cycler under the following conditions: 488C for 45 min, followed by 948C for 2 min and then by 30 cycles at 948C for 0.5 min, 608C for 1 min, and 688C for 2 min. RT ± PCR products were visualized by ethidium bromide staining after gel electrophoresis in 1.5% agarose. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was detected as a *150 bp band using the following primer pair: 5'-TGATGACAT-CAAGAAGGTGGTGAAG-3' and 5'-TCCTTGGAGGC-CATGTAGGCCAT-3'. MMP-1 was detected as a *350 bp band using the following primer pair: 5'-GTTCAGGGACA-GAATGTGCTA-3' and 5'-CTGCAGTTGAACCAGCTAT-TAG-3' ER81 was detected as a *250 bp band using the following primer pair: 5'-TCCCTCCATCGCAGTCCATA-3' and 5'-GGAAAGCTTTGGCTGGCCG-3'.
Analysis of 32 P-labeled ER81 6Myc-tagged ER81 was expressed in 293T cells that were labeled with 32 P-orthophosphate. Cells were lysed in 10 mM Tris pH 7.1, 30 mM Na 4 P 2 O 7 , 50 mM NaCl, 1% Triton X-100, 50 mM NaF, 0.5 mM Na 3 VO 4 , 10 mg/ml leupeptin, 2 mg/ ml aprotinin, 1 mg/ml pepstatin A, 0.5 mM phenylmethylsulfonyl¯uoride, 0.2 mM DTT. ER81 was then immunoprecipitated with monoclonal anti-Myc antibodies (9E10). The immunoprecipitate was electrophoresed on an SDS-9% polyacrylamide gel, the gel dried and the radiolabeled ER81 protein excised. After extraction of ER81 from the gel slice and performic acid treatment, a trypsin digestion was performed and the resulting phosphopeptides were resolved in two dimensions on thin layer chromatography plates (van der Geer and Hunter, 1994) .
